These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 23595576)

  • 21. Current approaches to the use of generic antiepileptic drugs.
    Krämer G; Biraben A; Carreno M; Guekht A; de Haan GJ; Jedrzejczak J; Josephs D; van Rijckevorsel K; Zaccara G
    Epilepsy Behav; 2007 Aug; 11(1):46-52. PubMed ID: 17537678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generic medicines in the Malaysian health care system: Opportunities and challenges.
    Wong ZY; Alrasheedy AA; Hassali MA; Saleem F
    Res Social Adm Pharm; 2016; 12(5):807-10. PubMed ID: 27157864
    [No Abstract]   [Full Text] [Related]  

  • 23. Estimation of Potential Savings Through Therapeutic Substitution.
    Johansen ME; Richardson C
    JAMA Intern Med; 2016 Jun; 176(6):769-75. PubMed ID: 27159226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Save green, go generic: be prepared to answer the $4 question.
    Hansen D
    S D Med; 2009 Nov; 62(11):436-7. PubMed ID: 20128174
    [No Abstract]   [Full Text] [Related]  

  • 25. Drug substitution associated with a hospital stay in Belgium: a retrospective analysis of a claims database.
    Simoens S; Dubois C; Spinewine A; Foulon V; Paulus D
    Int J Pharm Pract; 2014 Apr; 22(2):105-11. PubMed ID: 23829345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors influencing the use of the "not for generic substitution" mention for prescriptions in primary care: a survey with general practitioners.
    Beauvais V; Marque A; Ferté G; Chrusciel J; Souille J; Nazeyrollas P; Sanchez S
    BMC Health Serv Res; 2018 Nov; 18(1):850. PubMed ID: 30419890
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton pump inhibitors prescribing following the introduction of generic drugs.
    Cammarota S; Bruzzese D; Sarnelli G; Citarella A; Menditto E; Riegler S; Savino IG; Vozzella L; Piccinocchi G; Napoli L; Arpino G; Cuomo R
    Eur J Clin Invest; 2012 Oct; 42(10):1068-78. PubMed ID: 22681176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determinants of generic entry in the regulated Taiwanese prescription drug market.
    Liu YM; Cheng JS
    Health Policy; 2012 Dec; 108(2-3):228-35. PubMed ID: 23020970
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Generic dispensing rates for substitutable drugs prescribed by general practitioners compared with other private ambulatory specialists: A study based on a French national reimbursement database.
    Figoni H; Robert S; Bonello K; Ibanez G; Chastang J; Estellat C
    Eur J Gen Pract; 2024 Dec; 30(1):2407600. PubMed ID: 39397787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generic drugs in dermatology: part II.
    Payette M; Grant-Kels JM
    J Am Acad Dermatol; 2012 Mar; 66(3):353.e1-15; quiz 367-8. PubMed ID: 22342022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential Clinical and Economic Impact of Switching Branded Medications to Generics.
    Straka RJ; Keohane DJ; Liu LZ
    Am J Ther; 2017 May; 24(3):e278-e289. PubMed ID: 26099048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives of physicians practicing in low and middle income countries towards generic medicines: a narrative review.
    Hassali MA; Wong ZY; Alrasheedy AA; Saleem F; Mohamad Yahaya AH; Aljadhey H
    Health Policy; 2014 Sep; 117(3):297-310. PubMed ID: 25129135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A physician survey on generic drugs and substitution of critical dose medications.
    Banahan BF; Kolassa EM
    Arch Intern Med; 1997 Oct; 157(18):2080-8. PubMed ID: 9382664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating community pharmacists' perceptions of future generic substitution policy implementation: a national survey from Malaysia.
    Chong CP; Hassali MA; Bahari MB; Shafie AA
    Health Policy; 2010 Jan; 94(1):68-75. PubMed ID: 19762106
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Special considerations in generic substitution of immunosuppressive drugs in transplantation].
    Remport A; Dankó D; Gerlei Z; Czebe K; Kiss I
    Orv Hetil; 2012 Aug; 153(34):1341-9. PubMed ID: 22913916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential impact of implementing a system of generic substitution on the community drug schemes in Ireland.
    Tilson L; Bennett K; Barry M
    Eur J Health Econ; 2005 Sep; 6(3):267-73. PubMed ID: 15977036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.
    Duh MS; Cahill KE; Paradis PE; Cremieux PY; Greenberg PE
    Expert Opin Pharmacother; 2009 Oct; 10(14):2317-28. PubMed ID: 19663636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Encouraging generic use can yield significant savings.
    Zimmerman C
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient and physician reactions to generic antiepileptic substitution in the treatment of epilepsy.
    Haskins LS; Tomaszewski KJ; Crawford P
    Epilepsy Behav; 2005 Aug; 7(1):98-105. PubMed ID: 15961350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.
    Andermann F; Duh MS; Gosselin A; Paradis PE
    Epilepsia; 2007 Mar; 48(3):464-9. PubMed ID: 17346246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.